Why the study?
Do oral direct factor Xa inhibitors reduce strokes and other systemic embolic events compared to warfarin in patients with atrial fibrillation?
Do oral direct factor Xa inhibitors reduce strokes and other systemic embolic events compared to warfarin in patients with atrial fibrillation?
Oral direct factor Xa inhibitors significantly reduce the risk of stroke and systemic embolism compared to warfarin in patients with atrial fibrillation.
Supports preferential use of oral factor Xa inhibitors over warfarin in atrial fibrillation; reinforces pooled randomized evidence for stroke prevention.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: